The sound and the fury: Financial conflicts of interest in oncology

Journal of Clinical Oncology

Volumn 25, Issue 24, 2007, Pages 3567-3569

  Djulbegovic, Benjamin ^a   Angelotta, Cara ^a   Knox, Kjersti E ^a   Bennett, Charles L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CENTER; CANCER PREVENTION; CANCER RESEARCH; CLINICAL RESEARCH; CONFLICT OF INTEREST; DRUG INDUSTRY; EDITORIAL; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; MEDICAL PRACTICE; MEDICARE; ONCOLOGY; PRIORITY JOURNAL; UNITED STATES;

BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; DISCLOSURE; HEALTH CARE SECTOR; HUMANS; MEDICAL ONCOLOGY; RESEARCH SUPPORT; UNITED STATES;

EID: 34548479274     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9800     Document Type: Editorial

References (30)

1. Luce RD, Raiffa H: Games and Decisions. New York, NY, Dover Publications, 1957
2. Parascandola M: A turning point for conflicts of interest: The controversy over the National Academy of Sciences' first conflict of interest disclosure policy. J Clin Oncol 25:3609-3614, 2007
3. Bayh-Dole Act, 35 USC §200-212, 1980
4. Lexchin J, Bero LA, Djulbegovic B, et al: Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 326:1167-1170, 2003
5. Moses H III, Dorsey ER, Matheson DH, et al: Financial anatomy of biomedical research. JAMA 294:1333-1342, 2005
6. Barton JH, Emanuel EJ: The patents-based pharmaceutical development process: Rationale, problems, and potential reforms. JAMA 294:2075-2082, 2005
7. Stossel TP: Regulating academic-industrial research relationships: Solving problems or stifling progress? N Engl J Med 353:1060-1065, 2005
8. CBS News: Under the influence. http://www.cbsnews.com/stories/2007/03/29/ 60minutes/printable2625305.shtml
9. Angell M: The Truth About Drug Companies. New York, NY, Random House, 2004
10. Kassirer JP: On the Take: How Medicine's Complicity With Big Business Can Endanger Your Health. New York, NY, Oxford University Press, 2004
11. Kassirer J: On the take. New York, NY, Oxford University Press, 2005
12. Hampson LA, Joffe S, Fowler R: The frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. J Clin Oncol 25: 10.1200/JCO.2006.09.3633
13. Tversky A, Kahneman D: The framing of decisions and the psychology of choice. Science 211:453-458, 1981
14. Tversky A, Kahneman D: Prospect theory: An analysis of decisions under risk. Econometrica 47:263-291, 1979
15. Harris, Gardiner: FDA limits role of adviser tied to industry. New York Times, March 22, 2007, p A1
16. Ross JS, Lackner JE, Lurie P, et al: Pharmaceutical company payments to physicians: Early experiences with disclosure laws in Vermont and Minnesota. JAMA 297:1216-1223, 2007
17. Pharmaceutical Research and Manufacturers of America: Code on interactions with healthcare professionals. http://www.phrma.org/ code_on_interactions_with_healthcare_professionals/
18. American Medical Association: Gifts to physicians from industry. http://www.ama-assn.org/ama/pub/category/8484.html
19. American Society of Clinical Oncology: Revised conflict of interest policy. J Clin Oncol 24:519-521, 2006
20. Tanne JH: Investigators will review conflicts of interest at NIH. BMJ 334:767a, 2007
21. National Conference of State Legislatures: Pharmaceuticals: Overview and NCSL Resources Marketing and direct-to-consumer advertising of pharmaceuticals. http://www.ncsl.org/programs/health/pharm.htm
22. Brennan TA, Mello MM: Sunshine laws and the pharmaceutical industry. JAMA 297:1255-1257, 2007
23. Djulbegovic B, Cantor A, Clarke M: The importance of preservation of the ethical principle of equipoise in the design of clinical trials: Relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Account Res 10:301-315, 2003
24. Djulbegovic B, Lacevic M, Cantor A, et al: The uncertainty principle and industry-sponsored research. Lancet 356:635-638, 2000
25. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 289:454-465, 2003
26. Djulbegovic B, Adams JR, Lyman GH, et al: Evaluation and appraisal of randomized controlled trials in myeloma. Ann Oncol 12:1611-1617, 2001
27. Friedberg M, Saffran B, Stinson TJ, et al: Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282:1453-1457, 1999
28. Knox KS, Adams JR, Djulbegovic B: Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Ann Oncol 11:1591-1595, 2000
29. Dana J, Loewenstein G: A social science perspective on gifts to physicians from industry. JAMA 290:252-255, 2003
30. Parascandola M: Objectivity and the neutral expert. J Epidemiol Community Health 57:3-4, 2003